Registered title, quoted from ClinicalTrials.gov
Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by West China Hospital; 8 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 9
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorWest China Hospital四川大学华西医院ChengduHospital page
- Study siteFirst Affiliated Hospital of Chongqing Medical University重庆医科大学附属第一医院ChongqingHospital page
- Study siteFujian Provincial Hospital福建省立医院FuzhouHospital page
- Study siteJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
- Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
- Study siteSecond Affiliated Hospital of Chongqing Medical University重庆医科大学附属第二医院ChongqingHospital page
- Study siteSun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院GuangzhouHospital page
- Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
- Study siteZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07866612, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 8
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (8 points)Hide the checklist
18 years to 80 years; sex: all
Registered eligibility fields
HCC confirmed by histology or cytology or diagnosed according to accepted clinical diagnostic criteria. Histologic or cytologic confirmation is generally required for participants without cirrhosis.
Inclusion criterion 3
Child-Pugh class A and indocyanine green retention rate at 15 minutes (ICG R15) <30%.
Inclusion criterion 9
Previous treatment with a PD-1/PD-L1 inhibitor combined with a targeted or anti-angiogenic agent, with or without locoregional treatment such as transarterial chemoembolization, hepatic arterial infusion chemotherapy, radiotherapy, or ablation.
Inclusion criterion 5
Eastern Cooperative Oncology Group performance status of 0 or 1.
Inclusion criterion 13
Hemoglobin >=90 g/L;
Inclusion criterion 15
Absolute neutrophil count >=1.5 x 10\^9/L;
Inclusion criterion 16
Platelet count >=60 x 10\^9/L;
Inclusion criterion 17
Total bilirubin <=1.5 times the upper limit of normal (ULN);
Inclusion criterion 18
AST, ALT, and alkaline phosphatase <=2.5 times the ULN;
Inclusion criterion 19
Serum creatinine <=1.5 times the ULN or endogenous creatinine clearance >=50 mL/min;
Inclusion criterion 20
No active bleeding, with international normalized ratio <=1.5 times the ULN and activated partial thromboplastin time <=1.5 times the ULN.
Inclusion criterion 22
Another active malignancy within the previous 5 years, except for a malignancy treated with curative intent and considered to have a low risk of recurrence, such as carcinoma in situ of the cervix or nonmelanoma skin cancer.
Exclusion criterion 12
Women of childbearing potential must have a negative pregnancy test before randomization and agree to use effective contraception during study treatment and for the required period after the last dose. Nonsterilized men with partners of childbearing potential must also agree to use effective contraception.
Inclusion criterion 26
Pregnancy or breastfeeding.
Exclusion criterion 11
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07866612, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntary participation and provision of written informed consent.
- Age 18 to 80 years, inclusive.
- HCC confirmed by histology or cytology or diagnosed according to accepted clinical diagnostic criteria. Histologic or cytologic confirmation is generally required for participants without cirrhosis.
- No definite extrahepatic metastasis before initiation of the anticancer treatment that resulted in the current radiologic complete response (rCR).
- Previous treatment with a PD-1/PD-L1 inhibitor combined with a targeted or anti-angiogenic agent, with or without locoregional treatment such as transarterial chemoembolization, hepatic arterial infusion chemotherapy, radiotherapy, or ablation.
- Continued use of the same systemic regimen between the first documented rCR and confirmatory imaging. Dose modification or temporary interruption for toxicity is permitted, but changing treatment because of insufficient efficacy is not permitted.
- rCR confirmed according to mRECIST by repeat imaging performed 4 to 8 weeks after the first documented rCR.
- Multidisciplinary team assessment confirming that curative-intent liver resection is medically and technically feasible, R0 resection is expected to be achievable, and perioperative risk is acceptable.
- Child-Pugh class A and indocyanine green retention rate at 15 minutes (ICG R15) <30%.
- Future liver remnant (FLR) generally >=40% of standard liver volume (SLV) for participants with chronic liver disease, substantial hepatic parenchymal injury, or cirrhosis, and generally >=30% of SLV for participants without substantial fibrosis or cirrhosis.
- Pretreatment tumor thrombus involving the portal vein, hepatic vein, and/or inferior vena cava is permitted, but atrial tumor thrombus is not permitted. Previously present macrovascular tumor thrombus must show no definite radiologic activity after treatment and must be considered completely resectable by the multidisciplinary team.
- No extrahepatic metastasis or other active HCC lesion on contrast-enhanced CT and/or MRI of the chest, abdomen, and pelvis before randomization.
- Eastern Cooperative Oncology Group performance status of 0 or 1.
- Adequate organ function before randomization, including:
- Hemoglobin >=90 g/L;
- Absolute neutrophil count >=1.5 x 10\^9/L;
- Platelet count >=60 x 10\^9/L;
- Total bilirubin <=1.5 times the upper limit of normal (ULN);
- AST, ALT, and alkaline phosphatase <=2.5 times the ULN;
- Serum creatinine <=1.5 times the ULN or endogenous creatinine clearance >=50 mL/min;
- Urine protein <2+, or 24-hour urinary protein <1.0 g.
- No active bleeding, with international normalized ratio <=1.5 times the ULN and activated partial thromboplastin time <=1.5 times the ULN.
- Participants with hepatitis B virus infection must receive appropriate antiviral treatment according to local standards and agree to continue treatment during the study. Participants with an indication for antiviral treatment must start treatment during screening if they are not already receiving it.
- Participants with hepatitis C virus antibodies must undergo hepatitis C virus RNA testing and must not have active hepatitis C virus infection.
- Medically eligible for both surgical consolidation and continued systemic maintenance therapy and willing to receive the randomly assigned strategy.
- Women of childbearing potential must have a negative pregnancy test before randomization and agree to use effective contraception during study treatment and for the required period after the last dose. Nonsterilized men with partners of childbearing potential must also agree to use effective contraception.
Exclusion Criteria:
- Fibrolamellar HCC, sarcomatoid HCC, combined hepatocellular-cholangiocarcinoma, or another atypical HCC histologic subtype.
- Definite extrahepatic metastasis before initiation of the treatment that resulted in the current rCR, or any extrahepatic metastasis identified before randomization.
- Inability to undergo safe curative liver resection, an expectation that R0 resection cannot be achieved, or another medical factor that prevents surgical consolidation.
- Previous liver transplantation or current plans for liver transplantation.
- Decompensated cirrhosis or Child-Pugh class B or C hepatic function.
- Clinically significant and uncontrolled portal hypertension or another condition that substantially increases the perioperative risk of liver resection, including recurrent gastroesophageal variceal bleeding or refractory ascites.
- Active gastrointestinal bleeding within 4 weeks before randomization or a coagulation disorder that continues to fall outside study requirements after appropriate correction.
- Active infection, sepsis, or another serious infectious disease requiring systemic anti-infective treatment that may affect the safety of surgery or systemic therapy.
- Previous immune-related adverse events not recovered to Grade 1 or lower that may affect the safety of surgery or continued systemic treatment. Stable endocrine immune-related adverse events controlled with replacement therapy are permitted.
- Severe cardiac, pulmonary, renal, or other major organ dysfunction, or another serious comorbidity that would prevent tolerance of curative liver resection and/or continued systemic treatment.
- Pregnancy or breastfeeding.
- Another active malignancy within the previous 5 years, except for a malignancy treated with curative intent and considered to have a low risk of recurrence, such as carcinoma in situ of the cervix or nonmelanoma skin cancer.
- Inability to undergo standardized multiphase contrast-enhanced CT or MRI, or a condition that may substantially interfere with accurate radiologic assessment.
- A medical, psychological, social, or adherence-related factor that would prevent receipt of either randomized treatment strategy.
- Any other condition that, in the investigator's judgment, may affect participant safety, study adherence, or the reliability of study results and makes the individual unsuitable for participation.
Quoted from ClinicalTrials.gov, NCT07866612, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07866612, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.